Skip NavigationSkip to Content
Return Return to Search Results

Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody

  1. Author:
    Feng, Y.
    Xiao, X. D.
    Zhu, Z. Y.
    Dimitrov, D. S.

  2. Author Address

    [Feng, Yang; Xiao, Xiaodong; Zhu, Zhongyu; Dimitrov, Dimiter S.] NCI, Prot Interact Grp, CCRNP, NIH, Frederick, MD 21701 USA. [Zhu, Zhongyu] NCI, BRP, SAIC Frederick Inc, Frederick, MD 21701 USA.;Feng, Y, NCI, Prot Interact Grp, CCRNP, NIH, Frederick, MD 21701 USA.;fengya@mail.nih.gov
    1. Year: 2010
    2. Date: Sep-Oct
  2. Journal: Mabs
    1. 2
    2. 5
    3. Pages: 565-570
  4. Type of Article: Article
  5. ISSN: 1942-0862
  1. Abstract:

    The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been established as promising targets for cancer treatment. Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors, but they also synergize with traditional therapies and show efficacy against tumors that are otherwise resistant to conventional treatments. We describe here the identification and characterization of two human monoclonal antibodies, m921 and m922, that are specific for human DR4. Both antibodies competed with TRAIL for binding to DR4, but only m921 recognized cell surface-associated DR4 and inhibited the growth of ST486 cells. This antibody may have potential for further development as a candidate therapeutic and research tool.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.4161/mabs.2.5.12570
  3. View record in Web of Science®
  4. WOS: 000283634100011

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel